Overall, the future of patients with MCL is promising, since therapeutic options have widened. The implementation of universal aggressive treatment is challenged by novel regimens, targeted agents, the use of MRD to guide treatment decisions, and new trials that will directly compare transplant vs non-transplant approaches.
We are ready to move beyond a “one-size-fits-all” approach in AML and join our colleagues treating other malignancies, such as lung cancer, in moving towards a personalized medicine approach.
On April 11, 2016, The US Food and Drug Administration approved a new agent for patients with chronic lymphocytic leukemia.
A first-in-man phase I study of CUDC-907, which targets both histone deacetylase and PI3K enzymes, has shown promise in patients with relapsed or refractory multiple myeloma or lymphoma.
The long-term use of romidepsin in a dose-sparing regimen to treat cutaneous T-cell lymphoma may be a useful strategy to try to prolong disease response.
A significant number of children who have completed treatment for acute lymphoblastic leukemia may be experiencing anxiety or depression, according to a new study.
Patients with acute myeloid leukemia who have undergone autologous stem cell transplantation and survived without disease recurrence for at least 2 years are still at risk for late recurrences.
Patients with CML who are treated with dasatinib commonly experience lymphocytosis, and the condition is associated with higher response rates and increased survival in patients who are refractory or intolerant of imatinib.
The injectable drug APO866, designed to induce apoptosis, did not have efficacy against cutaneous T-cell lymphoma, according to the results of small study.
Elevated levels of TGF-α and IL-6 in newly diagnosed chronic-phase chronic myeloid leukemia patients were predictive of failure to achieve molecular response.
A study found an increased incidence of non-Hodgkin lymphoma, but no other secondary malignancies, in chronic myeloid leukemia patients treated with imatinib.
Temsirolimus produced some responses in patients with relapsed/refractory primary central nervous system lymphoma, but the responses tended to be short-lived.
Patients with chronic phase CML and pre-existing mild to moderate liver and/or renal dysfunction can be safely treated with frontline nilotinib or dasatinib, according to a new study.
Although a child’s socioeconomic status did not seem to significantly affect 5-year overall survival ALL, those children who were from high-poverty areas experienced early relapse compared with children who were from low-poverty areas.
Individuals with increased height or body mass index during adolescence showed an increased association with a diagnosis of non-Hodgkin lymphoma.
A phase I trial found that blinatumomab, a bispecific T-cell engager antibody, is feasible with regard to safety for treatment of patients with relapsed or refractory non-Hodgkin lymphoma.
A new personalized DNA-based assay can detect very low levels of persistent disease in chronic myeloid leukemia patients thought to be in deep remission.
A number of clinical and sociodemographic factors, including age and gender, were found to be independently associated with fatigue and depression among cancer patients who were treated with hematopoietic cell transplantation.
Five-year results of the randomized phase III ENESTnd trial show a positive risk-benefit profile for nilotinib in patients with CML, as compared to imatinib.
Treatment with the BCR-ABL tyrosine kinase inhibitors dasatinib, nilotinib, and ponatinib was associated with increased risk for vascular occlusive events in patients with CML compared with imatinib.
Older patients with AML who are ineligible for intensive chemotherapy achieved improved overall survival when assigned to low-dose gemtuzumab ozogamicin.
Laboratory studies of mice and human cells found that a protein called Metastasis suppressor 1 (Mtss1) is downregulated in hematopoietic and progenitor cells when chronic myeloid leukemia is present. Mtss1 levels are restored when complete remission is achieved, suggesting the pathway might represent a new therapeutic target.
Survivors of thyroid cancer are at an increased risk for developing a second cancer, according to the results of a recently published study.
A laboratory study found that the Hhex protein is overexpressed in acute myeloid leukemia cells and is necessary for their propagation but not for normal myelopoiesis.
